BE2015C046I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2015C046I2 BE2015C046I2 BE2015C046C BE2015C046C BE2015C046I2 BE 2015C046 I2 BE2015C046 I2 BE 2015C046I2 BE 2015C046 C BE2015C046 C BE 2015C046C BE 2015C046 C BE2015C046 C BE 2015C046C BE 2015C046 I2 BE2015C046 I2 BE 2015C046I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001187105 | 2001-06-20 | ||
JP2001243046 | 2001-08-09 | ||
JP2001311808 | 2001-10-09 | ||
JP2001398708 | 2001-12-28 | ||
PCT/JP2002/002683 WO2003000657A1 (en) | 2001-06-20 | 2002-03-20 | Diamine derivatives |
PCT/JP2002/006141 WO2003000680A1 (en) | 2001-06-20 | 2002-06-20 | Diamine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2015C046I2 true BE2015C046I2 (en) | 2021-07-19 |
Family
ID=27482359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2015C046C BE2015C046I2 (en) | 2001-06-20 | 2015-07-16 |
Country Status (13)
Country | Link |
---|---|
US (7) | US7365205B2 (en) |
EP (1) | EP2343290A1 (en) |
AR (1) | AR036102A1 (en) |
BE (1) | BE2015C046I2 (en) |
CY (2) | CY1113054T1 (en) |
FR (1) | FR15C0068I2 (en) |
HK (1) | HK1092461A1 (en) |
MY (1) | MY153231A (en) |
NL (1) | NL300760I2 (en) |
PT (1) | PT1405852E (en) |
TW (1) | TWI298066B (en) |
WO (1) | WO2003000657A1 (en) |
ZA (1) | ZA200309866B (en) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US7365205B2 (en) * | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
RU2319699C2 (en) * | 2001-06-20 | 2008-03-20 | Дайити Санкио Компани, Лимитед | Derivatives of diamines |
IL160204A0 (en) * | 2001-08-09 | 2004-07-25 | Daiichi Seiyaku Co | Diamine derivatives |
CA2511493A1 (en) * | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
US7205318B2 (en) * | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
WO2005032490A2 (en) * | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Cyclic diamines and derivatives as factor xa inhibitors |
KR101215153B1 (en) | 2003-11-12 | 2012-12-24 | 다이이찌 산쿄 가부시키가이샤 | Process for producing thiazole derivative |
KR20060128976A (en) * | 2003-12-29 | 2006-12-14 | 세프라코 아이엔시. | Pyrrole and pyrazole daao inhibitors |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
CN101001850A (en) * | 2004-06-24 | 2007-07-18 | 因塞特公司 | Amido compounds and their use as pharmaceuticals |
JP2008504278A (en) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | Amide compounds and their use as pharmaceuticals |
EP1773780A4 (en) * | 2004-06-24 | 2008-01-09 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
CA2589565A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
JP2008504280A (en) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | 2-methylpropanamide and its pharmaceutical use |
JP2008504275A (en) | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | N-substituted piperidines and their use as pharmaceuticals |
KR20070050076A (en) * | 2004-08-10 | 2007-05-14 | 인사이트 산 디에고 인코포레이티드 | Amido compounds and their use as pharmaceuticals |
US7499687B2 (en) * | 2004-11-09 | 2009-03-03 | Theta Microelectronics, Inc. | Wireless transmitter DC offset recalibration |
US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
EP1824842A4 (en) * | 2004-11-18 | 2009-08-26 | Incyte Corp | Inhibitors of 11- hydroxyl steroid dehydrogenase type 1 and methods of using the same |
EE200700051A (en) * | 2005-02-18 | 2007-12-17 | Arpida Ag | Method for the preparation of 2H-chromene and intermediates |
KR20070116032A (en) * | 2005-03-31 | 2007-12-06 | 다이이찌 산쿄 가부시키가이샤 | Triamine derivative |
WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
TW200745033A (en) | 2005-09-14 | 2007-12-16 | Dainippon Sumitomo Pharma Co | Oxindole derivative as feeding control agent |
JP4510088B2 (en) * | 2005-09-16 | 2010-07-21 | 第一三共株式会社 | Optically active diamine derivative and method for producing the same |
WO2007038138A2 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
KR101415861B1 (en) * | 2005-12-05 | 2014-07-04 | 인사이트 코포레이션 | Lactam compounds and methods of using the same |
KR101294014B1 (en) | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | Cycloalkylamines as monoamine reuptake inhibitors |
CN104276955A (en) * | 2006-01-06 | 2015-01-14 | 赛诺维信制药公司 | Tetralone-based monoamine reuptake inhibitors |
US7998959B2 (en) * | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
AU2007210018A1 (en) * | 2006-01-31 | 2007-08-09 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
TW200808807A (en) * | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
AU2007233041B2 (en) | 2006-03-31 | 2013-05-02 | Sepracor Inc. | Preparation of chiral amides and amines |
EP2013163A1 (en) * | 2006-05-01 | 2009-01-14 | Incyte Corporation | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
EP2018378A2 (en) * | 2006-05-17 | 2009-01-28 | Incyte Corporation | Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
JP2009544616A (en) * | 2006-07-21 | 2009-12-17 | 武田薬品工業株式会社 | Amide compounds |
WO2008026563A1 (en) | 2006-08-30 | 2008-03-06 | Shionogi & Co., Ltd. | Hydrazine amide derivative |
ZA200904686B (en) * | 2007-01-18 | 2010-09-29 | Sepracor Inc | Inhibitiors of D-amino acid oxidase |
US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
EP2140867B2 (en) * | 2007-03-29 | 2023-08-16 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
EP2617704B1 (en) | 2007-05-31 | 2017-06-28 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
DE102007028406A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
DE102007028407A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
DE102007028319A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
CL2008001839A1 (en) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases. |
GB0721333D0 (en) * | 2007-10-31 | 2007-12-12 | Motac Neuroscience Ltd | Medicaments |
US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
US9776963B2 (en) | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
KR20110106840A (en) | 2008-12-12 | 2011-09-29 | 다이이찌 산쿄 가부시키가이샤 | Process for producing optically active carboxylic acid |
CN102256984B (en) | 2008-12-17 | 2014-09-03 | 第一三共株式会社 | Method for producing diamine derivative |
JPWO2010082531A1 (en) * | 2009-01-13 | 2012-07-05 | 第一三共株式会社 | Activated blood coagulation factor inhibitor |
JP5666424B2 (en) * | 2009-03-10 | 2015-02-12 | 第一三共株式会社 | Method for producing diamine derivative |
WO2010104106A1 (en) | 2009-03-13 | 2010-09-16 | 第一三共株式会社 | Method for producing optically active diamine derivative |
WO2010131663A1 (en) * | 2009-05-15 | 2010-11-18 | 第一三共株式会社 | Oxamide derivative |
WO2010147169A1 (en) | 2009-06-18 | 2010-12-23 | 第一三共株式会社 | Pharmaceutical composition having improved solubility |
FR2948372B1 (en) | 2009-07-21 | 2011-07-22 | Servier Lab | NOVEL CHROMENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
TW201132646A (en) | 2010-02-22 | 2011-10-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
TW201141544A (en) | 2010-02-22 | 2011-12-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
EP2540294B1 (en) | 2010-02-22 | 2016-08-03 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
JP5692873B2 (en) * | 2010-03-19 | 2015-04-01 | 第一三共株式会社 | Crystal of diamine derivative and method for producing the same |
CA2793525C (en) | 2010-03-19 | 2014-05-06 | Daiichi Sankyo Company, Limited | Method for improving dissolution of anticoagulant agent |
WO2011149110A1 (en) | 2010-05-28 | 2011-12-01 | Daiichi Sankyo Company, Limited | Novel composition for the prevention and/or treatment of thromboembolism |
TWI630209B (en) | 2010-07-02 | 2018-07-21 | 第一三共股份有限公司 | Production method for a salt-form of optically active diamine |
HUP1000598A2 (en) | 2010-11-05 | 2012-09-28 | Richter Gedeon Nyrt | Indole derivatives |
CN103619883A (en) | 2011-01-19 | 2014-03-05 | 拜耳知识产权有限责任公司 | Binding proteins to inhibitors of coagulation factors |
JP5860050B2 (en) | 2011-07-08 | 2016-02-16 | 第一三共株式会社 | Product quality control method |
CA2844604C (en) | 2011-08-10 | 2017-07-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing ethanediamide derivatives |
US20130158069A1 (en) | 2011-12-14 | 2013-06-20 | Daiichi Sankyo Company, Limited | Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment |
CN102659757B (en) * | 2012-04-24 | 2013-11-06 | 南京药石药物研发有限公司 | Intermediate synthesizing 5-chlorothiophene-3-carbo and preparation method thereof |
KR102127625B1 (en) | 2012-09-03 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition |
BR112015004666B1 (en) | 2012-09-07 | 2022-04-26 | Novartis Ag | Indole carboxamide derivatives, their use, and pharmaceutical composition |
KR20150085513A (en) | 2012-11-23 | 2015-07-23 | 다이이찌 산쿄 가부시키가이샤 | Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1] octan-7-one |
MX2015011514A (en) | 2013-03-15 | 2016-08-11 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof. |
KR102350704B1 (en) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | Heteroaryl compounds and uses thereof |
BR112015019669A2 (en) * | 2013-03-29 | 2017-07-18 | Daiichi Sankyo Co Ltd | production method of a compound |
TWI602803B (en) | 2013-03-29 | 2017-10-21 | 第一三共股份有限公司 | Preparation method of optically active diamine compound |
EP3038620A1 (en) | 2013-08-29 | 2016-07-06 | Daiichi Sankyo Co., Ltd. | Agent for the treatment and prevention of cancer |
WO2015150950A1 (en) | 2014-03-31 | 2015-10-08 | Daiichi Sankyo Company, Limited | Use of a factor xa inhibitor for treating and preventing bleeding events and related disorders in patients having sensitivity to vitamin k antagonists used as anticoagulants |
DE102014108210A1 (en) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | rodenticide |
US9975848B2 (en) | 2014-08-13 | 2018-05-22 | The Trustees Of The University Of Pennsylvania | Inhibitors of HIV-1 entry and methods of use thereof |
CN104529729B (en) * | 2014-12-31 | 2016-03-30 | 浙江永太科技股份有限公司 | The preparation method of the fluoro-3-chlorobenzaldehyde of a kind of 2- |
TWI571460B (en) | 2016-03-14 | 2017-02-21 | 中化合成生技股份有限公司 | Process for producing diamine derivative |
JP6831447B2 (en) | 2016-07-13 | 2021-02-17 | マイラン ラボラトリーズ リミテッドMylan Laboratories Limited | Amine-protected (1S, 2R, 4S) -1,2-amino-N, N-dimethylcyclohexane-4-carboxamide salt |
WO2018069769A1 (en) | 2016-10-13 | 2018-04-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for inhibiting neointima formation of blood vessel |
US10301322B2 (en) | 2016-12-27 | 2019-05-28 | Apotex Inc. | Processes for the preparation of edoxaban and intermediates thereof |
MX2019010717A (en) * | 2017-03-10 | 2019-12-05 | Univ Rutgers | Indole derivatives as efflux pump inhibitors. |
GB201807014D0 (en) | 2018-04-30 | 2018-06-13 | Univ Leeds Innovations Ltd | Factor xlla inhibitors |
TWI826474B (en) | 2018-06-27 | 2023-12-21 | 日商第一三共股份有限公司 | Granules containing diamine derivative, as well as use and manufacturing method thereof |
MX2021003382A (en) | 2018-09-26 | 2021-05-27 | Jiangsu Hengrui Medicine Co | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof. |
US20210347894A1 (en) | 2018-09-30 | 2021-11-11 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
CN109942600B (en) * | 2019-04-15 | 2021-08-20 | 内蒙古京东药业有限公司 | Preparation method of edoxaban |
BR112022000185A2 (en) | 2019-07-10 | 2022-02-22 | Bayer Ag | Method of preparation of 2-(phenylimino)-1,3-thiazolidin-4-ones |
KR102333564B1 (en) | 2019-11-28 | 2021-12-01 | 동방에프티엘(주) | A novel synthetic route for the production of optically active diamine derivative and thiazole derivate |
BR112022011032A2 (en) | 2019-12-12 | 2022-08-16 | Jiangsu Hengrui Medicine Co | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF |
BR112022014189A2 (en) | 2020-01-22 | 2022-11-29 | Jiangsu Hengrui Medicine Co | ANTI-TROP-2 ANTIBODY CONJUGATE EXATECAN ANALOG AND MEDICAL USE OF IT |
CA3177279A1 (en) | 2020-03-25 | 2021-09-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-psma antibody-exatecan analogue conjugate and medical use thereof |
CN115103858A (en) | 2020-03-25 | 2022-09-23 | 江苏恒瑞医药股份有限公司 | Preparation method of antibody drug conjugate |
KR20220157998A (en) | 2020-03-25 | 2022-11-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pharmaceutical Compositions Comprising Antibody Drug Conjugates and Uses Thereof |
WO2021249228A1 (en) | 2020-06-08 | 2021-12-16 | 四川百利药业有限责任公司 | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
KR20220087933A (en) | 2020-12-18 | 2022-06-27 | 엠에프씨 주식회사 | Method For Producing Diamine Derivative |
EP4262760A1 (en) | 2020-12-18 | 2023-10-25 | KRKA, d.d., Novo mesto | Edoxaban formulation containing no sugar alcohols |
EP4070658A1 (en) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Use of anticoagulant active compounds as rodenticide |
GB202107722D0 (en) | 2021-05-28 | 2021-07-14 | Lunac Therapeutics Ltd | Factor XIIA Inhibitors |
CN114456194B (en) * | 2021-12-14 | 2023-07-07 | 浙江九洲药业股份有限公司 | Intermediate of Ai Duosha class tosylate and preparation method thereof |
CN115583900A (en) * | 2022-04-29 | 2023-01-10 | 张邦成都生物医药科技有限公司 | Preparation method of high-purity ixaban intermediate |
WO2023223346A1 (en) | 2022-05-16 | 2023-11-23 | Mylan Laboratories Limited | An improved process for the preparation of edoxaban intermediate |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3376268A (en) * | 1964-02-26 | 1968-04-02 | Monsanto Co | Amide-heterocyclic polymers |
EP0224566A1 (en) * | 1985-06-07 | 1987-06-10 | The Upjohn Company | Antiarrhythmic use for aminocycloalkylamides |
WO1992004017A1 (en) * | 1990-09-10 | 1992-03-19 | The Upjohn Company | Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants |
IL100576A (en) | 1991-01-18 | 1995-11-27 | Eli Lilley And Company | Cephalosporin antibiotics |
AU2913292A (en) | 1991-11-14 | 1993-06-15 | Bernard Derek Frutin | A pressurised container |
US5430150A (en) * | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
WO1994020062A2 (en) | 1993-03-03 | 1994-09-15 | Eli Lilly And Company | Balanoids as protein kinase c inhibitors |
JP2680196B2 (en) | 1993-03-17 | 1997-11-19 | 明治製菓株式会社 | Novel compound having inhibitory effect on platelet aggregation |
KR970001164B1 (en) | 1993-06-09 | 1997-01-29 | 한국과학기술연구원 | Cephalosporin antibiotics and their process for preparing them |
EP0725059B1 (en) | 1993-10-19 | 2001-01-17 | Sumitomo Pharmaceuticals Company, Limited | 2,3-diaminopropionic acid derivative |
TW270114B (en) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
US5525042A (en) | 1993-11-08 | 1996-06-11 | Clearline Systems, Inc. | Liquid pump with compressed gas motive fluid |
US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
WO1995032965A1 (en) | 1994-06-01 | 1995-12-07 | Yamanouchi Pharmaceutical Co. Ltd. | Oxadiazole derivative and medicinal composition thereof |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
EP0820452B1 (en) | 1995-04-07 | 2003-06-04 | Schering Corporation | Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase |
ZA963391B (en) | 1995-05-24 | 1997-10-29 | Du Pont Merck Pharma | Isoxazoline fibrinogen receptor antagonists. |
US5726126A (en) | 1995-06-02 | 1998-03-10 | American Cyanamid Company | 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
DE19536783A1 (en) * | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunctional nicotinamide chelating agents of the type N¶2¶S¶2¶ for radioactive isotopes |
US5852045A (en) | 1995-10-19 | 1998-12-22 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
GB9602294D0 (en) | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
IL126610A0 (en) | 1996-04-17 | 1999-08-17 | Du Pont Pharm Co | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors |
US5668159A (en) | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
AU3701797A (en) | 1996-08-14 | 1998-03-06 | Zeneca Limited | Substituted pyrimidine derivatives and their pharmaceutical use |
UA56197C2 (en) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Heterocyclic derivatives |
WO1998035956A1 (en) | 1997-02-13 | 1998-08-20 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
IT1291823B1 (en) | 1997-04-08 | 1999-01-21 | Menarini Ricerche Spa | PSEUDO-PEPTIDE COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS |
ATE334975T1 (en) | 1997-05-30 | 2006-08-15 | Takeda Pharmaceutical | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE |
US6207679B1 (en) | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
IL133621A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
IL133627A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
JP2002510313A (en) | 1997-06-26 | 2002-04-02 | イーライ・リリー・アンド・カンパニー | Antithrombotic substance |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
BR9815377A (en) | 1997-09-30 | 2001-01-16 | Daiichi Pharmaceutical Co Ltda | Sulfonyl derivatives |
AR013693A1 (en) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | NEW PIPERIDINES AND PIPERAZINAS AS INHIBITORS OF THE PLAQUETARY AGREGATION |
US6130349A (en) * | 1997-12-19 | 2000-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Catalytic compositions and methods for asymmetric allylic alkylation |
EP0937723A1 (en) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Novel sulfonamides, process for their preparation and medicaments containing them |
EP0937711A1 (en) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Thiobenzamides, process for their preparation and medicaments containing them |
GB9807104D0 (en) | 1998-04-02 | 1998-06-03 | Chirotech Technology Ltd | The preparation of phosphine ligands |
DE19814801A1 (en) * | 1998-04-02 | 1999-10-07 | Basf Ag | Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts |
WO1999054308A1 (en) | 1998-04-21 | 1999-10-28 | Du Pont Pharmaceuticals Company | 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
GB9809349D0 (en) | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Heterocyclic derivatives |
DE69921994T2 (en) | 1998-05-02 | 2005-12-01 | Astrazeneca Ab | HETEROCYCLIC COMPOUNDS WITH FACTOR XA HARDENING EFFECT |
GB9809350D0 (en) | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Novel salt |
CA2329770A1 (en) | 1998-06-30 | 2000-01-06 | Ian Campbell Lennon | The preparation of arylphosphines |
JP2000086659A (en) | 1998-07-14 | 2000-03-28 | Takeda Chem Ind Ltd | Octahydropyrido[1,2-alpha]pyrazine derivative |
TW434207B (en) | 1998-07-24 | 2001-05-16 | Everlight Chem Ind Corp | Chiral ligand and method for preparing cyanohydrins from aldehydes |
US6303625B1 (en) | 1998-07-27 | 2001-10-16 | Ortho-Mcneil Pharmaceutical, Inc. | Triazolopyridines for the treatment of thrombosis disorders |
CA2340100A1 (en) | 1998-08-11 | 2000-02-24 | Daiichi Pharmaceutical Co., Ltd. | Novel sulfonyl derivatives |
DE69931393T2 (en) | 1998-12-23 | 2007-03-29 | Eli Lilly And Co., Indianapolis | ANTITHROMBOTIC AMIDE |
ES2196917T3 (en) | 1998-12-23 | 2003-12-16 | Lilly Co Eli | HETEROAROMATIC AMIDES AS INHIBITORS OF FACTOR XA`. |
US6635657B1 (en) | 1998-12-23 | 2003-10-21 | Eli Lilly And Company | Aromatic amides |
ES2217879T3 (en) | 1998-12-24 | 2004-11-01 | Eli Lilly And Company | HETEROCICLIC AMIDAS. |
GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
AU2241400A (en) * | 1999-04-06 | 2000-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | Novel thiazolobenzoimidazole derivative |
JP4390024B2 (en) | 1999-04-23 | 2009-12-24 | アステラス製薬株式会社 | Novel diazepane derivatives or salts thereof |
GB9909592D0 (en) * | 1999-04-26 | 1999-06-23 | Chirotech Technology Ltd | Process for the preparation of calanolide precursors |
WO2000071515A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc | INHIBITORS OF FACTOR Xa |
CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
EP1185488A1 (en) * | 1999-06-15 | 2002-03-13 | Rhodia Chimie | Sulphonylamides and carboxamides and their use in asymmetrical catalysis |
GB9914342D0 (en) | 1999-06-19 | 1999-08-18 | Zeneca Ltd | Compound |
JP2001011071A (en) | 1999-06-25 | 2001-01-16 | Mochida Pharmaceut Co Ltd | Aminoalkylsulfonamide derivative |
US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
GB9917344D0 (en) | 1999-07-24 | 1999-09-22 | Zeneca Ltd | Novel salt |
ATE253558T1 (en) | 1999-09-13 | 2003-11-15 | Dimensional Pharm Inc | AZAZYKLOAL CANNONE SERINE PROTEASE INHIBITORS |
TR200201413T2 (en) | 1999-09-17 | 2003-02-21 | Millennium Pharmaceuticals, Inc. | Inhibitors of Factor Xa. |
IL155155A0 (en) | 1999-09-17 | 2003-10-31 | Cor Therapeutics Inc | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
AU1770001A (en) | 1999-11-24 | 2001-06-04 | Cor Therapeutics, Inc. | Beta-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factorxa |
AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US6586418B2 (en) | 2000-06-29 | 2003-07-01 | Bristol-Myers Squibb Company | Thrombin or factor Xa inhibitors |
EP1322643A1 (en) | 2000-09-29 | 2003-07-02 | Millennium Pharmaceuticals, Inc. | Piperazin-2-one amides as inhibitors of factor xa |
AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
EP1322610A2 (en) | 2000-09-29 | 2003-07-02 | Millennium Pharmaceuticals, Inc. | PIPERAZINE BASED INHIBITORS OF FACTOR Xa |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
WO2002042270A1 (en) | 2000-11-22 | 2002-05-30 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted benzene derivatives or salts thereof |
EP1343751A2 (en) | 2000-12-20 | 2003-09-17 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
EP1373194B1 (en) | 2001-03-30 | 2007-08-01 | Millennium Pharmaceuticals, Inc. | BENZAMIDE INHIBITORS OF FACTOR Xa |
US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
RU2319699C2 (en) | 2001-06-20 | 2008-03-20 | Дайити Санкио Компани, Лимитед | Derivatives of diamines |
IL160204A0 (en) | 2001-08-09 | 2004-07-25 | Daiichi Seiyaku Co | Diamine derivatives |
BRPI0212726B8 (en) | 2001-09-21 | 2021-05-25 | Bristol Myers Squibb Co | compounds containing lactams, and derivatives thereof, pharmaceutical composition comprising them and their uses |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
WO2003099276A1 (en) | 2002-05-10 | 2003-12-04 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
WO2004058728A1 (en) * | 2002-12-24 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | Novel ethylenediamine derivatives |
CA2511493A1 (en) * | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
-
2002
- 2002-03-20 US US10/481,262 patent/US7365205B2/en active Active
- 2002-03-20 WO PCT/JP2002/002683 patent/WO2003000657A1/en active Application Filing
- 2002-06-19 MY MYPI20022307A patent/MY153231A/en unknown
- 2002-06-20 AR ARP020102322A patent/AR036102A1/en active IP Right Grant
- 2002-06-20 PT PT02743653T patent/PT1405852E/en unknown
- 2002-06-20 TW TW091113510A patent/TWI298066B/en active
- 2002-06-20 EP EP11002212A patent/EP2343290A1/en not_active Withdrawn
-
2003
- 2003-12-19 ZA ZA2003/09866A patent/ZA200309866B/en unknown
-
2004
- 2004-02-09 US US10/773,344 patent/US7342014B2/en not_active Expired - Lifetime
-
2006
- 2006-11-24 HK HK06112922.2A patent/HK1092461A1/en not_active IP Right Cessation
-
2007
- 2007-09-06 US US11/850,788 patent/US20080015215A1/en not_active Abandoned
-
2008
- 2008-12-30 US US12/259,496 patent/US20100093785A1/en not_active Abandoned
-
2009
- 2009-03-06 US US12/399,702 patent/US20090270446A1/en not_active Abandoned
-
2010
- 2010-05-21 US US12/784,710 patent/US20110077266A1/en not_active Abandoned
- 2010-12-13 US US12/966,640 patent/US20110312990A1/en not_active Abandoned
-
2012
- 2012-08-20 CY CY20121100742T patent/CY1113054T1/en unknown
-
2015
- 2015-07-16 BE BE2015C046C patent/BE2015C046I2/fr unknown
- 2015-08-20 CY CY2015034C patent/CY2015034I2/en unknown
- 2015-09-29 NL NL300760C patent/NL300760I2/en unknown
- 2015-10-09 FR FR15C0068C patent/FR15C0068I2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US7342014B2 (en) | 2008-03-11 |
CY2015034I1 (en) | 2016-04-13 |
EP2343290A1 (en) | 2011-07-13 |
TWI298066B (en) | 2008-06-21 |
CY1113054T1 (en) | 2016-04-13 |
US20080015215A1 (en) | 2008-01-17 |
ZA200309866B (en) | 2005-03-30 |
MY153231A (en) | 2015-01-29 |
US7365205B2 (en) | 2008-04-29 |
HK1092461A1 (en) | 2007-02-09 |
US20090270446A1 (en) | 2009-10-29 |
PT1405852E (en) | 2012-10-30 |
CY2015034I2 (en) | 2016-04-13 |
US20110077266A1 (en) | 2011-03-31 |
US20110312990A1 (en) | 2011-12-22 |
US20050020645A1 (en) | 2005-01-27 |
US20050119486A1 (en) | 2005-06-02 |
FR15C0068I2 (en) | 2016-04-22 |
AR036102A1 (en) | 2004-08-11 |
US20100093785A1 (en) | 2010-04-15 |
NL300760I2 (en) | 2017-07-20 |
WO2003000657A1 (en) | 2003-01-03 |
FR15C0068I1 (en) | 2015-12-04 |